PRKDC and obesity due to melanocortin 4 receptor deficiency: The intricate role of DNA‐PK in metabolic regulation underscores its potential as a therapeutic target for obesity and diabetes, with partial inhibition offering benefits without the adverse effects associated with complete loss of activity.